8-K: AngioDynamics Focuses on Cardiovascular Care with Innovative Technologies at Investor Event

AngioDynamics highlights its strategic focus on cardiovascular and cancer care, emphasizing innovative technologies and improved patient outcomes at its Cardiovascular Investor Event.

Summary

• AngioDynamics held a Cardiovascular Investor Event on April 2, 2025, to discuss its focus on cardiovascular disease and cancer treatment.
• The company's strategy is built on innovative R&D, clinical and regulatory pathway expansion, and customer-centric sales performance.
• AngioDynamics estimates the US Total Addressable Market (TAM) for Venous Thromboembolism (VTE) to be $5.3 billion, Prostate Care to be $780 million, and Peripheral Artery Disease (PAD) to be $760 million.
• The Auryon Atherectomy System is projected to exceed cumulative sales of $180 million since its launch in September 2020, having treated over 100,000 patients.
• Mechanical Thrombectomy is estimated to have penetrated approximately 15% of the TAM for Deep Vein Thrombosis (DVT) and 25% of the TAM for Pulmonary Embolism (PE).
• The company expects to be Adjusted EBITDA positive by FY2025 and cash flow positive by FY2026.
• AngioDynamics' Med Tech segment operates in key markets with unique technologies that deliver proven clinical outcomes.
• The AlphaVac F1885 System received FDA clearance for Pulmonary Embolism (PE) in April 2024, following the APEX-AV study.
• The APEX-AV study demonstrated a significant reduction in clot burden with AlphaVac F1885 compared to competitive technologies.
• The company maintains a debt-free, strong balance sheet.

Sentiment

Score: 7

Explanation: The document presents a positive outlook for AngioDynamics, highlighting its strategic focus, innovative technologies, and expected financial improvements. However, it also acknowledges the risks and uncertainties associated with forward-looking statements, which tempers the overall sentiment.

Positives

• AngioDynamics has a strong track record in portfolio management, R&D, clinical and regulatory expansion, and customer-centric sales & marketing.
• The company maintains a debt-free, strong balance sheet.
• The AlphaVac F1885 System received FDA clearance for Pulmonary Embolism (PE) in April 2024.
• The Auryon Atherectomy System has treated over 100,000 patients.
• The company expects to be Adjusted EBITDA positive by FY2025 and cash flow positive by FY2026.

Risks

• The document contains forward-looking statements that are subject to risks and uncertainties.
• Factors that may affect actual results include the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics technology, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2024.

Future Outlook

AngioDynamics expects to be Adjusted EBITDA positive by FY2025 and cash flow positive by FY2026, positioning the company for sustainable revenue growth and profit for years to come.

Industry Context

AngioDynamics is operating in the growing medical technology market, focusing on cardiovascular and cancer care, which are significant areas of unmet need. The company's focus on innovative technologies and clinical outcomes aligns with the industry's trend towards minimally invasive procedures and improved patient care.

Comparison to Industry Standards

• The document references Penumbra, Inc. as a competitor in the thrombectomy space.
• The APEX-AV trial results for AlphaVac F1885 are compared to the FLARE study for FlowTriever and the EXTRACT-PE trial for the Indigo Aspiration System, highlighting AlphaVac's superior reduction in clot burden.
• The document mentions AngioDynamics' Auryon system competing with products from ABT, BSX, PHG and MDT in the Peripheral Artery Disease (PAD) market.

Stakeholder Impact

• Shareholders can expect potential revenue growth and profitability.
• Patients can benefit from innovative technologies and improved treatment options.
• Employees may experience growth opportunities within the company.

Key Dates

Keywords

AngioDynamics, cardiovascular, cancer, Auryon, AlphaVac, thrombectomy, atherectomy, medical devices, VTE, PAD, PE, DVT